文献速递小儿麻醉气道管理

舒更葡糖引入对儿科医院神经肌肉阻滞和气管插管使用的影响:回顾性观察性横断面研究

Impact of Sugammadex Introduction on Using Neuromuscular Blockade and Endotracheal Intubation in a Pediatric Hospital: A Retrospective, Observational Cross-Sectional Study.
PubMed 文献 · Anesth Analg · 2024-07-26

单中心回顾性横断面研究纳入25,638例2-17岁全麻手术患儿,比较舒更葡糖引入前(2014-2016)、早期(2017-2019)和成熟期(2020-2022)的实践变化。调整分析显示,神经肌肉阻滞药使用几率显著增加(2017-2019年OR 1.55,2020-2022年OR 5.62),气管插管使用几率下降(OR 0.69和0.71),且年龄较大儿童和住院医师在场与阻滞药使用增加相关。

要点

  • 舒更葡糖引入后,儿科全麻中神经肌肉阻滞药使用几率显著增加。
  • 同期气管插管使用几率下降,但住院医师诱导时插管几率仍较高。
  • 年龄较大儿童和住院医师负责的病例更倾向于使用神经肌肉阻滞药。

核心结论

  • 舒更葡糖可用后,麻醉计划中使用神经肌肉阻滞药的决定大幅增加,尤其在年龄较大儿童和住院医师负责的病例中。
  • 研究期间气管插管使用下降。

研究设计与样本

  • 单中心回顾性观察性横断面研究,纳入2至17岁全麻手术患儿25,638例。
  • 比较2014-2016年(舒更葡糖前)、2017-2019年(早期)和2020-2022年(成熟期)三个时间段。
  • 使用广义线性混合模型分析实践模式变化。

主要发现

  • 调整分析中,神经肌肉阻滞药使用几率从2017-2019年(OR 1.55,95%CI 1.38-1.75)和2020-2022年(OR 5.62,95%CI 4.96-6.37)相对于2014-2016年增加。
  • 年龄6-11岁 vs 2-5岁使用阻滞药的OR为1.81(95%CI 1.63-2.01),12-17岁 vs 2-5岁OR为7.01(95%CI 6.19-7.92)。
  • 住院医师为主要室内提供者 vs 认证注册麻醉护士(CRNA)使用阻滞药的OR为1.24(95%CI 1.12-1.37)。
  • 气管插管使用几率2017-2019年OR为0.69(95%CI 0.63-0.75),2020-2022年OR为0.71(95%CI 0.65-0.78)。
  • 年龄6-11岁 vs 2-5岁插管OR为0.45(95%CI 0.42-0.49),12-17岁 vs 2-5岁OR为0.28(95%CI 0.25-0.31);住院医师诱导时插管OR为1.50(95%CI 1.38-1.62)。

临床怎么用

  • 儿科麻醉中舒更葡糖的可用性可能促使更多使用神经肌肉阻滞药,需关注住院医师培训中的决策模式。
  • 尽管插管总体下降,但住院医师在场时插管几率仍较高,提示需平衡气道管理选择。

局限性

  • 单中心回顾性设计,可能存在未测量混杂因素。
  • 研究结果可能不适用于其他机构或人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sugammadex is a neuromuscular blockade (NMB) reversal agent introduced in the United States in 2016, which allows the reversal of deep NMB, not possible with neostigmine. Few data describe associated practice changes, if any, in NMB medication use that may have resulted from its availability. We hypothesized that after institutional introduction, use of NMB agents increased. Furthermore, as NMB medication is typically used when the airway has been secured with an endotracheal tube (ETT), we speculated that ETT use may have also increased over the same time period as a result of sugammadex availability. METHODS: This was a single-center cross-sectional study of patients ages 2 to 17 years undergoing general anesthesia for surgical cases where anesthesia providers often have discretion over NMB medication use or whether to use an ETT versus a laryngeal mask airway (LMA), comparing the time periods 2014 to 2016 (presugammadex) to 2017 to 2019 (early sugammadex) and 2020 to 2022 (established sugammadex). Outcomes included use of (1) any nondepolarizing NMB medication during the case and (2) an ETT versus LMA. We used generalized linear mixed models to examine changes in practice patterns over time. We also examined whether patient age group and in-room provider (resident versus certified registered nurse anesthetist [CRNA]) were associated with increased NMB medication or ETT use. RESULTS: There were 25,638 eligible anesthetics. Patient and surgical characteristics were similar across time periods. In adjusted analyses, the odds of NMB medication use increased from 2017 to 2019 (odds ratio [OR], 1.55, 95% confidence interval [CI], 1.38-1.75) and 2020 to 2022 (OR, 5.62, 95% CI, 4.96-6.37) relative to 2014 to 2016, and were higher in older children (age 6-11 years vs 2-5 years OR, 1.81, 95% CI, 1.63-2.01; age 12-17 years vs 2-5 years OR, 7.01, 95% CI, 6.19-7.92) and when the primary in-room provider was a resident rather than a CRNA (OR, 1.24, 95% CI, 1.12-1.37). The odds of ETT use declined 2017 to 2019 (OR, 0.69, 95% CI, 0.63-0.75) and 2020 to 2022 (OR, 0.71, 95% CI, 0.65-0.78), more so in older children (age 6-11 years vs 2-5 years OR, 0.45, 95% CI, 0.42-0.49; age 12-17 years vs 2-5 years OR, 0.28, 95% CI, 0.25-0.31). Resident presence at induction was associated with increased odds of ETT use (OR, 1.50, 95% CI, 1.38-1.62). CONCLUSIONS: The decision to use NMB medication as part of an anesthetic plan increased substantially after sugammadex became available, particularly in older children and cases staffed by residents. ETT use declined over the study period.

来源:Anesth Analg,查看原文。版权归原作者所有。

引用

  1. Brown SES, Cassidy R, Zhao X, et al. Impact of Sugammadex Introduction on Using Neuromuscular Blockade and Endotracheal Intubation in a Pediatric Hospital: A Retrospective, Observational Cross-Sectional Study. Anesth Analg. 2024. PMID: 39058621. doi:10.1213/ANE.0000000000007048

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。